Item 8.01. Other Events.



On June 26, 2021, BeiGene, Ltd. (the "Company" or "BeiGene") announced that
BRUKINSA® (zanubrutinib) has been approved by Health Canada for the treatment of
mantle cell lymphoma (MCL) in adult patients who have received at least one
prior therapy. This is the second approval for BRUKINSA in Canada, following its
initial approval in March 2021 for adult patients with Waldenström's
macroglobulinemia (WM). The full text of this press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On June 29, 2021, the Company announced positive topline results from an interim
analysis of the Phase 3 SEQUOIA trial comparing BRUKINSA® (zanubrutinib) to
bendamustine and rituximab (B+R) in patients with treatment-naïve (TN) chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose tumor did
not exhibit the deletion of chromosome 17p13.1 (del[17p]). The full text of this
press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is
incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Announces Approval in Canada of BRUKINSA®
                          (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma",
                          issued by BeiGene, Ltd. on June 26, 2021.

       99.2               Press Release titled "BeiGene Announces Positive

Topline Results from Phase 3


                          SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib)

to Bendamustine Plus


                          Rituximab in Patients with Treatment-Naïve

Chronic Lymphocytic Leukemia",


                          issued by BeiGene, Ltd. on June 29, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL


--------------------------------------------------------------------------------


                                 Exhibit Index

   Exhibit No.            Description

       99.1                 Press Release titled "    BeiGene Announces Approval in Canada of
                          BRUKINSA    ®     (Zanubrutinib) for the

Treatment of Patients with Mantle


                          Cell Lymphoma    ", issued by BeiGene, Ltd. on

June 2 6 , 2021.



       99.2                 Press Release titled "    BeiGene Announces

Positive Topline Results from


                          Phase 3 SEQUOIA Trial Comparing     BRUKINSA

® (Zanubrutinib) to


                          Bendamustine Plus Rituximab in Patients with

Treatment-Naïve Chronic


                            Lymphocytic Leukemia    ", issued by BeiGene,

Ltd. on June 29, 2021.


       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses